3rd Rare & Genetic Kidney Disease Drug Development Summit
With the pivotal acceptance of eGFR as a surrogate endpoint along with the advances in genetic therapies and disease pathology sequencing, the floodgates for faster approval and developments in precision medicine for patients with rare and genetic kidney diseases have opened. Reuniting the community dedicated to advancing the frontier of novel therapies in IgAN, Alport Syndrome, FSGS, PKD and more, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is your exclusive industry meeting to share and leverage instrumental insights needed to better understand patients’ unique experiences, kidney-specific mode of action, and adaptive trial designs. Join 100+ experts from the FDA, EMA, HI-Bio, Chinook Therapeutics, Novo Nordisk, Janssen, Travere Therapeutics, Otsuka, and many more to unlock the potential of RNA-based therapeutics, unravel biomarkers and their use within precision medicine, and reduce the barriers to clinical trial diversity.
8c10.jpg)
